Detection of Unknown and Rare Pathogenic Variants in Antithrombin, Protein C and Protein S Deficiency Using High-Throughput Targeted Sequencing
Petr Vrtel,
Ludek Slavik,
Radek Vodicka,
Julia Stellmachova,
Martin Prochazka,
Jana Prochazkova,
Jana Ulehlova,
Peter Rohon,
Tomas Simurda,
Jan Stasko,
Ivana Martinkova,
Radek Vrtel
Affiliations
Petr Vrtel
Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Ludek Slavik
Department of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Radek Vodicka
Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Julia Stellmachova
Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Martin Prochazka
Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Jana Prochazkova
Department of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Jana Ulehlova
Department of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Peter Rohon
Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic
Tomas Simurda
National Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, 03659 Martin, Slovakia
Jan Stasko
National Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, 03659 Martin, Slovakia
The deficiency of natural anticoagulants—antithrombin (AT), protein C (PC), and protein S (PS)—is a highly predisposing factor for thrombosis, which is still underdiagnosed at the genetic level. We aimed to establish and evaluate an optimal diagnostic approach based on a high-throughput sequencing platform suitable for testing a small number of genes. A fast, flexible, and efficient method involving automated amplicon library preparation and target sequencing on the Ion Torrent platform was optimized. The cohort consisted of a group of 31 unrelated patients selected for sequencing due to repeatedly low levels of one of the anticoagulant proteins (11 AT-deficient, 13 PC-deficient, and 7 PS-deficient patients). The overall mutation detection rate was 67.7%, highest in PC deficiency (76.9%), and six variants were newly detected—SERPINC1 c.398A > T (p.Gln133Leu), PROC c.450C > A (p.Tyr150Ter), c.715G > C (p.Gly239Arg) and c.866C > G (p.Pro289Arg), and PROS1 c.1468delA (p.Ile490fs) and c.1931T > A (p.Ile644Asn). Our data are consistent with those of previous studies, which mostly used time-consuming Sanger sequencing for genotyping, and the indication criteria for molecular genetic testing were adapted to this process in the past. Our promising results allow for a wider application of the described methodology in clinical practice, which will enable a suitable expansion of the group of indicated patients to include individuals with severe clinical findings of thrombosis at a young age. Moreover, this approach is flexible and applicable to other oligogenic panels.